Sroubek J, Matos J, Locke A, et al. - Researchers undertook this prospective analysis to determine whether N-terminal pro–B-type natriuretic peptide (NT-proBNP) has utility as a predictor of appropriate implantable cardioverter-defibrillator (ICD) therapies in primary prevention ICD recipients. Participants were 342 stable patients exhibiting left ventricular ejection fraction ≤ 40%. These patients received a primary prevention ICD. At the time of device implant, NT-proBNP assay was performed. NT-proBNP was employed as a dichotomized variable to predict primary (appropriate ICD therapies) as well as secondary (mortality, ICD-deactivation, chronic inotropic support, transplant) outcomes. As per findings, NT-proBNP was identified as a reasonable as well as a specific predictor of future appropriate device therapies in primary prevention ICD recipients, as revealed in multivariable analysis. All-cause death was not predicted by adjusted NT-proBNP.